142 related articles for article (PubMed ID: 17275669)
21. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T
Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855
[TBL] [Abstract][Full Text] [Related]
22. The first case of 3-methylcrotonyl-CoA carboxylase (MCC) deficiency responsive to biotin.
Friebel D; von der Hagen M; Baumgartner ER; Fowler B; Hahn G; Feyh P; Heubner G; Baumgartner MR; Hoffmann GF
Neuropediatrics; 2006 Apr; 37(2):72-8. PubMed ID: 16773504
[TBL] [Abstract][Full Text] [Related]
23. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
[TBL] [Abstract][Full Text] [Related]
24. [Therapy of multiple sclerosis].
Simó M
Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
[TBL] [Abstract][Full Text] [Related]
25. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
[TBL] [Abstract][Full Text] [Related]
26. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
27. Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study.
Webb UH
J Neurosci Nurs; 2008 Dec; 40(6):356-61. PubMed ID: 19170303
[TBL] [Abstract][Full Text] [Related]
28. [Interferon-beta treatment in patients with childhood-onset and juvenile multiple sclerosis].
Totolian NA; Skoromets AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(9):23-31. PubMed ID: 15490937
[TBL] [Abstract][Full Text] [Related]
29. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
Debouverie M; Taillandier L; Pittion-Vouyovitch S; Louis S; Vespignani H
Mult Scler; 2007 Jun; 13(5):626-31. PubMed ID: 17548442
[TBL] [Abstract][Full Text] [Related]
30. 3-Methylcrotonyl-CoA carboxylase deficiency: metabolic decompensation in a noncompliant child detected through newborn screening.
Ficicioglu C; Payan I
Pediatrics; 2006 Dec; 118(6):2555-6. PubMed ID: 17142544
[TBL] [Abstract][Full Text] [Related]
31. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
32. [Severe Raynaud's phenomenon associated with interferon-beta 1a and fluoxetine].
De Broucker T; Lhote F
Ann Med Interne (Paris); 2000 Sep; 151(5):424-5. PubMed ID: 11033481
[No Abstract] [Full Text] [Related]
33. Combined MRI lesions and relapses as a surrogate for disability in MS.
Ebers GC; Scalfari A; Daumer M; Lederer C
Neurology; 2012 Apr; 78(17):1367; author reply 1367. PubMed ID: 22529206
[No Abstract] [Full Text] [Related]
34. Diagnosis and management of multiple sclerosis: case studies.
Woo DA; Olek MJ; Frohman EM
Neurol Clin; 2006 May; 24(2):199-214. PubMed ID: 16684629
[TBL] [Abstract][Full Text] [Related]
35. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[TBL] [Abstract][Full Text] [Related]
36. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic role of mitoxantrone in multiple sclerosis.
Neuhaus O; Kieseier BC; Hartung HP
Pharmacol Ther; 2006 Jan; 109(1-2):198-209. PubMed ID: 16095713
[TBL] [Abstract][Full Text] [Related]
38. Sclerosing skin disorders in association with multiple sclerosis. Coincidence, underlying autoimmune pathology or interferon induced?
Hügle T; Gratzl S; Daikeler T; Frey D; Tyndall A; Walker UA
Ann Rheum Dis; 2009 Jan; 68(1):47-50. PubMed ID: 18203763
[TBL] [Abstract][Full Text] [Related]
39. [3-Methylcrotonyl-CoA carboxylase deficiency].
Yoshida I
Ryoikibetsu Shokogun Shirizu; 1998; (18 Pt 1):284-7. PubMed ID: 9590048
[No Abstract] [Full Text] [Related]
40. Narcolepsy-like syndrome in multiple sclerosis.
Vetrugno R; Stecchi S; Plazzi G; Lodi R; D'Angelo R; Alessandria M; Cortelli P; Montagna P
Sleep Med; 2009 Mar; 10(3):389-91. PubMed ID: 18550429
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
